Ironwood Pharmaceuticals Inc SEC filings IRWD
Ironwood Pharmaceuticals Inc has 1,003 filings in SEC EDGAR's recent list, going back to Nov 4, 2014. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2026 | Jun 16, 2026 |
| DEFA14A | Additional proxy material | Apr 28, 2025 | — |
| DEF 14A | Proxy statement | Apr 28, 2025 | Jun 10, 2025 |
| DEFA14A | Additional proxy material | Apr 25, 2024 | — |
| DEF 14A | Proxy statement | Apr 25, 2024 | Jun 18, 2024 |
| DEFA14A | Additional proxy material | Apr 27, 2023 | — |
| DEF 14A | Proxy statement | Apr 27, 2023 | — |
| DEFA14A | Additional proxy material | Apr 21, 2022 | — |
| DEF 14A | Proxy statement | Apr 21, 2022 | Jun 1, 2022 |
| DEFA14A | Additional proxy material | Apr 22, 2021 | — |
| DEF 14A | Proxy statement | Apr 22, 2021 | Jun 2, 2021 |
| DEFA14A | Additional proxy material | Apr 21, 2020 | — |
| DEF 14A | Proxy statement | Apr 21, 2020 | Jun 3, 2020 |
| DEF 14A | Proxy statement | Apr 26, 2019 | May 30, 2019 |
| PRE 14A | Preliminary proxy statement | Apr 12, 2019 | May 30, 2019 |
| DEFA14A | Additional proxy material | May 14, 2018 | — |
| DEFA14A | Additional proxy material | May 14, 2018 | — |
| DEFA14A | Additional proxy material | May 9, 2018 | — |
| DEFA14A | Additional proxy material | May 9, 2018 | — |
| DEFA14A | Additional proxy material | May 2, 2018 | — |
| DEFA14A | Additional proxy material | May 2, 2018 | — |
| DEFA14A | Additional proxy material | May 2, 2018 | — |
| DEFA14A | Additional proxy material | May 1, 2018 | — |
| DEFA14A | Additional proxy material | May 1, 2018 | — |
| DEFA14A | Additional proxy material | Apr 9, 2018 | — |
| DEFA14A | Additional proxy material | Apr 18, 2017 | — |
| DEF 14A | Proxy statement | Apr 18, 2017 | May 31, 2017 |
| DEFA14A | Additional proxy material | Apr 15, 2016 | — |
| DEF 14A | Proxy statement | Apr 15, 2016 | Jun 1, 2016 |
| DEFA14A | Additional proxy material | Apr 17, 2015 | — |
| DEF 14A | Proxy statement | Apr 17, 2015 | Jun 3, 2015 |
Showing 32 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IRWD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1446847
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.